Latest News and Press Releases

GaraHerb supplement facts and ingredient disclosures verified from official label sources. 2026 overview of male enhancement supplement options.

Cupids Hypnosis 2.0 pheromone cologne ingredient disclosures, PheroPureVXN™ blend details, and what consumers are researching in this category.

BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

PORTLAND, Ore., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, today announced that the U.S. Food and Drug...

Chicago, Feb. 06, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global process analytical technology market is projected to add an opportunity of US$ 4,923.41 Mn...

VANCOUVER, British Columbia, Feb. 06, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – Money is moving fast. We are watching a structural realignment where capital migrates from sugary...

Ottawa, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Increasing surgical volumes, home-based care, and automation in fluid and waste handling are creating sustained growth opportunities in the healthcare fluid...

Ottawa, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The global advanced coating for healthcare packaging market was valued at USD 3.05 billion in 2025 and is expected to grow to USD 6.71 billion in 2035, as...

According to market projections, the CBD pet market to grow from USD 329 million in 2024 to USD 5476.42 million by 2034, reflecting a CAGR of 32.5%.

Ottawa, Feb. 06, 2026 (GLOBE NEWSWIRE) -- According to Precedence Research, the global generic drugs market size is projected to reach nearly USD 762.48 billion by 2035, growing from USD 491.67...

NEW YORK and SUNSET BEACH, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:...

The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas...

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the...

Chicago, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The global medical devices market was valued at 517.86 billion in 2024 and is expected to reach US$ 905.56 billion by 2033, growing at a CAGR of 6.4% from...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6...

Chicago, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The global neurostimulation devices market was valued at 9.84 billion in 2024 and is expected to reach US$ 22.64 billion by 2033, growing at a CAGR of 9.7%...

Austin, United States, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Orthopedic Implants Market Size & Growth Analysis: According to SNS Insider, the Orthopedic Implants Market is estimated at USD 23.50...

Dublin, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The "Cannabis Use Disorder Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" report has been added to ...

The global Anti-obesity Drugs market is projected to grow at a CAGR of 24.2% to reach US$195.99 billion by 2036.

Allschwil, Switzerland – February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker...

Hims GLP-1 weight loss update: reported $49 compounded semaglutide pill, FDA vs. compounded distinctions, and telehealth access details for 2026

PharmaZee telehealth platform information updated. Examining compounded vs FDA-approved GLP-1s amid Novo Nordisk compounding statement Feb 2026.

ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company...

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech...

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor...

CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...

WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced...

5. februar 2026Meddelelse nr. 1 BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en...

February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business...

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness...

“Cell Therapy Processing: Global Markets and Technologies” is estimated to grow from $2.7 billion in 2025 to reach $7.1 billion by 2030.

2025 revenue Full-year revenue: €786.4 million, down 3.5% at CER1 and on a like-for-like basis2, largely due to the fall in business in FranceA decline in Q4 of 5.6% at CER and on a like-for-like...

Chiffre d’affaires 2025 Chiffre d’affaires annuel : 786,4 M€, soit un repli de 3,5% à TCC1 et périmètre comparable2, largement dû à la baisse de l’activité en FranceAu quatrième trimestre, une baisse...

The global generative AI in life sciences market size is worth around USD 233.74 million in 2024 and is to reach around USD 1,544.13 million by 2034.

According to market projections, the AI in healthcare market to grow from USD 37.98 bn in 2025 to USD 928.18 bn by 2035, reflecting a CAGR of 37.66%.

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether certain officers and directors of Atkore Inc. (NYSE: ATKR), Axsome Therapeutics, Inc. (NASDAQ: AXSM),...

Corcept Therapeutics Shareholders - Contact Bernstein Liebhard For More Information Regarding Shareholder Investigation

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Replimune Group, Inc. (NASDAQ: REPL), Sable...

The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safet

The global cosmetic chemicals market size is valued at USD 26.81 billion in 2025 to reach USD 52.14 billion by 2035.

The global digital therapeutics market size is valued at USD 9.73 billion in 2025 and is to reach around USD 56.76 billion by 2034.

VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad...

– Live video webcast on Wednesday, February 11th at 1:20 PM EST   HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced...

Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.

– Seasoned clinical development leader brings more than 25 years of deep expertise in clinical development and operations across biotech and healthcare industry – SAN DIEGO, Calif., Feb. 05, 2026 ...

PathMaker Neurosystems Board Director, John Donoghue, Ph.D., Awarded 2026 Queen Elizabeth Prize for Engineering

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies